The European Medicines Agency (EMA) has announced its recommendation for marketing authorization of mCombriax, Moderna's innovative combined mRNA vaccine designed to protect older adults against both COVID-19 and influenza.This endorsement was made by the EMA's Committee for Medicinal Products for Human Use, following a comprehensive review of data from a phase 3 trial that involved 8,000 participants aged 50 and older.
Source:
cidrap.umn.eduThe trial results indicated that participants who received mCombriax exhibited immune responses that were non-inferior to those who received either Moderna's licensed COVID-19 vaccine, Spikevax, or authorized flu vaccines, including Fluzone and Fluarix.
Source:
cidrap.umn.eduIf the European Commission accepts the EMA's recommendation, mCombriax will become available across the European Union, providing individuals with the option of receiving a single shot to protect against both illnesses.
Source:
cidrap.umn.eduIn a statement, Moderna's CEO, Stephane Bancel, emphasized the significance of this recommendation, calling it an important milestone for respiratory virus vaccination and for the company itself.Bancel noted that combination vaccines have the potential to simplify vaccination processes, which could lead to improved health outcomes for the population.
Source:
cidrap.umn.eduThe EMA highlighted that national authorities will ultimately determine which vaccines to deploy and how they will be recommended to the public, taking into account the specific health situations in their respective countries.
Source:
cidrap.umn.eduThis flexibility allows countries to tailor their vaccination campaigns based on local health needs and population demographics.The recommendation comes at a time when the ongoing threat of COVID-19 and seasonal influenza continues to pose significant public health challenges, particularly for vulnerable groups such as older adults.
Source:
who.intVaccination remains a critical tool in preventing severe disease and reducing mortality associated with these viruses.
Source:
en.wikipedia.orgThe combined vaccine is particularly relevant given the lessons learned during the COVID-19 pandemic.Vaccines have played a crucial role in reducing the spread of the virus and the severity of the disease, with estimates suggesting that COVID-19 vaccines saved at least 14.4 million lives globally in 2021 alone.
Source:
who.intThe introduction of mCombriax could enhance vaccination coverage by streamlining the administration process for two significant respiratory illnesses.
Source:
cidrap.umn.eduModerna had previously submitted a Biologic License Application to the US Food and Drug Administration (FDA) for mCombriax in 2024.However, the application was withdrawn in May 2025 after the FDA requested additional data.
Source:
cidrap.umn.eduThe EMA's current recommendation may serve as a catalyst for future approvals in other regions as well.Overall, the EMA's positive assessment of mCombriax underscores the ongoing commitment to advancing public health through innovative vaccine development and the potential for combination vaccines to address multiple health threats simultaneously.
Source:
cidrap.umn.eduAs the situation evolves, continued monitoring and research will be essential to ensure the safety and efficacy of this new vaccine option in real-world settings.
Sources:
who.inten.wikipedia.orgThe approval of mCombriax not only represents a potential advancement in the fight against respiratory infections but also signals a broader shift towards more integrated vaccination strategies that could help manage public health more effectively in the years to come.
